These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 11565623)

  • 21. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP; Heel RC
    Drugs; 1985 Mar; 29(3):189-207. PubMed ID: 3886352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects.
    Parrott AC; Wesnes K
    Psychopharmacology (Berl); 1987; 92(4):513-9. PubMed ID: 3114803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of transdermal scopolamine and dimenhydrinate in acute vestibular disease].
    Wolf M; Kronenberg J; Leventon G
    Harefuah; 1987 Aug; 113(3-4):65-6. PubMed ID: 3500900
    [No Abstract]   [Full Text] [Related]  

  • 24. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cinnarizine in the prevention of seasickness.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    Aviat Space Environ Med; 1994 Jul; 65(7):606-9. PubMed ID: 7945126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central effects of cinnarizine: restricted use in aircrew.
    Nicholson AN; Stone BM; Turner C; Mills SL
    Aviat Space Environ Med; 2002 Jun; 73(6):570-4. PubMed ID: 12056673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of some motion sickness suppressants on static and dynamic tracking performance.
    Schroeder DJ; Collins WE; Elam GW
    Aviat Space Environ Med; 1985 Apr; 56(4):344-50. PubMed ID: 3994616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine.
    Weerts AP; Pattyn N; Putcha L; Hoag SW; Van Ombergen A; Hallgren E; Van de Heyning PH; Wuyts FL
    J Psychopharmacol; 2015 Dec; 29(12):1231-5. PubMed ID: 26268532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.
    Scholtz AW; Steindl R; Burchardi N; Bognar-Steinberg I; Baumann W
    Clin Drug Investig; 2012 Jun; 32(6):387-99. PubMed ID: 22506537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Sea Sickness in Susceptible Flight Crews.
    Powell-Dunford N; Bushby A
    Mil Med; 2017 Nov; 182(11):e1846-e1850. PubMed ID: 29087851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.
    Pyykkö I; Schalén L; Jäntti V
    Acta Otolaryngol; 1985; 99(5-6):588-96. PubMed ID: 4024909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of scopolamine on matching to sample paradigm and related tests in human subjects.
    Koller G; Satzger W; Adam M; Wagner M; Kathmann N; Soyka M; Engel R
    Neuropsychobiology; 2003; 48(2):87-94. PubMed ID: 14504417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. INM investigations into drugs for seasickness prophylaxis.
    Pingree BJ
    J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study.
    Hahn A; Novotný M; Shotekov PM; Cirek Z; Bognar-Steinberg I; Baumann W
    Clin Drug Investig; 2011; 31(6):371-83. PubMed ID: 21401214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.
    Klöcker N; Hanschke W; Toussaint S; Verse T
    Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seasickness treatment with cinnarizine.
    Dolmierski R
    Bull Inst Marit Trop Med Gdynia; 1983; 34(3-4):215-6. PubMed ID: 6681365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.
    Scholtz AW; Waldfahrer F; Hampel R; Weisshaar G
    Clin Drug Investig; 2022 Sep; 42(9):705-720. PubMed ID: 35864302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.